Return to content in this issue


Dupilumab: a Review of Present Indications and Uses Out Of Indication

Francisco Javier Muñoz-Bellido1,2,3,4, Esther Moreno1,2,3,4, Ignacio Dávila1,2,3

1Allergy Service. Hospital Universitario de Salamanca
2Instituto Biosanitario de Salamanca, Salamanca
3Department of Biomedical and Diagnostic Sciences. University of Salamanca, Salamanca
4RETIC Asma, Reacciones adversas y Alérgicas ARADyAL

J Investig Allergol Clin Immunol 2022; Vol. 32(2)
doi: 10.18176/jiaci.0682

Recent advances in understanding T2 inflammation have broadened the diseases in which T2 inflammation can be involved. Dupilumab is a recently developed monoclonal antibody blocking the signaling of both IL-4 and IL13, two crucial cytokines of the T2 responses. New possible indications are increasingly exploring. Among them are skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, among other several cutaneous diseases. Also, respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy are two more research fields. Here we review the published data and clinical trials about the use of dupilumab in these disorders.

Key words: Dupilumab, Alopecia areata, Allergic bronchopulmonary aspergillosis, Allergic contact dermatitis, Chronic urticaria, Eosinophilic esophagitis, Cutaneous autoimmune bullous diseases, Food allergy